EKE. A. Kitsenko

E. A. Kitsenko

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


E. A. Kitsenko has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Acute Simultaneous Thrombosis of the Hepatic Veins and the Portal System in a 30-Year-Old Female with JAK2-Positive Essential Thrombocythemia

    by S. A. Slyadnev, A. N. Bashkov, A. L. Melikyan, I. N. Subortseva, E. A. Gilyazitdinova, Zh. V. Tratsevskaya, L. S. Baysaeva, E. A. Kitsenko, O. А. Soboleva

    Aim: to present a clinical case of simultaneous thrombosis of the hepatic veins and total thrombosis of the vessels of the portal system in a myeloproliferative neoplasm. Key points. The patient was admitted to the gastroenterology department with complaints of abdominal distension, abdominal pain syndrome, and hyperthermia. An examination revealed widespread thrombosis of the hepatic veins and the portal system. Conservative therapy with diuretics, low-molecular-weight heparins, and albumin preparations proved ineffective. The patient was referred to a federal clinic for verification of the diagnosis of myeloproliferative neoplasm. As a result of the examination, a diagnosis of essential thrombocythemia was established. Against the background of comprehensive conservative therapy, a regression of refractory ascites was achieved. The patient is under dynamic observation of a hematologist, a hepatologist, hepatobiliary surgeon, and a transplantologist.

  • Modern approaches to the management of complications of extrahepatic portal hypertension due to extensive portal system thrombosis

    by S.V. Fedorchenko, G.V. Manukyan, S.L. Malov, E.E. Fandeyev, D.N. Mazanova, E.A. Kitsenko

    This article provides a systematic review of current literature on extensive portal system thrombosis. It examines etiology, pathogenesis, classifications, clinical manifestations, diagnosis, and comprehensive management of this condition. The particular focus is placed on the differentiated approach to a treatment strategy—ranging from anticoagulant therapy to endovascular and surgical interventions. The relevance of the topic is underscored by the high frequency of life-threatening complications, such as gastroesophageal variceal bleeding, portal cholangiopathy and mesenteric ischemia. This work aims to synthesize contemporary knowledge on the management of patients with portal system thrombosis to optimize diagnostic and therapeutic algorithms.

  • Open Access

    Pregnancy Management in Patients with Ph-Negative Myeloproliferative Neoplasms: A Literature Review and Case Report

    by Kristina Teimurazovna Poghosyan, A. L. Melikyan, E. A. Gilyazitdinova, I. N. Subortseva, Z. V. Tratsevskaya, E. S. Polushkina, E. E. Sudneva, E. A. Kitsenko

    Myeloproliferative neoplasms (MPNs) refer to a range of chronic oncohematologic clonal diseases characterized by excessive proliferation of myeloid lineage cells and/or excessive fibrosis of the bone marrow. Although MPNs are commonly diagnosed in subjects over 60 years of age, it is now increasingly detected at a young age. It is not uncommon for practitioners to encounter young pregnant patients with Ph-negative MPNs. Both pregnancy and Ph-negative MPNs are characterized by hypercoagulation increasing the risk of thrombotic complications and other adverse events associated with placental insufficiency. Pregnant MPN patients are treated with antiaggregants (aspirin) and anticoagulants (low molecular weight heparin), erythrocytapheresis or bloodletting; interferon-α is used if cytoreduction is required. This paper reports a case of management and outcomes of four pregnancies in a patient with masked polycythemia vera marked by portal vein thrombosis, portal hypertension, splenomegaly as well as esophageal and gastric fundus varices. Her first pregnancy ended in miscarriage at the early stage of gestation, her second pregnancy resulted in a premature birth, whereas her third and fourth pregnancies were successful — she delivered full-term babies. During all pregnancies, the patient received interferon-α.

  • Open Access

    Esophagogastric Bleedings in Patients with Ph-Negative Myeloproliferative Neoplasms and Extrahepatic Portal Hypertension

    by Pavel Artemovich Batrov, K. I. Danishian, E. P. Sysoeva, K. R. Sabirov, O. M. Averbukh, O. A. Soboleva, E.A. Kitsenko Kitsenko, E. A. Lukina

    AIM. To assess the treatment outcomes in esophagogastric bleeding patients with Ph-negative myeloproliferative neoplasms (MPN) and extrahepatic portal hypertension caused by thrombotic complications. MATERIALS & METHODS. The present prospective clinical trial performed in the surgical department of the National Research Center for Hematology from 2013 to 2024 enrolled 52 patients with Ph-negative MPNs and extrahepatic portal hypertension caused by total portal vein thrombosis. The median age of patients was 45 years (range 25–68 years). Young (≤ 40 years) and middle-aged (≤ 60 years) patients predominated: 16 (30.8 %) and 31 (59.6 %), respectively. There were 5 (9.6 %) elderly (> 60 years) patients. The V617F mutation in JAK2 was detected in 41 (78.8 %) out of 52 patients. RESULTS. Splenectomy was performed in 49 patients, 41 (78.8 %) out of them also underwent gastrotomy as well as esophageal/gastric variceal ligation. Gastrotomy was not carried out in 10 (19.2 %) out of 52 patients. Laparotomy with gastrotomy along with esophageal and gastric variceal ligation (without splenectomy) was performed in 3 (5.8 %) patients. Repeated bleedings were registered in 2 of them, which required further splenectomy. Overall incidence of postoperative complications was 21 %. Long-term rebleedings reported in 7 (13.5 %) patients were treated non-surgically. The 5-year overall survival in the total group (n = 52) was 90.1 %. At later stages of Ph-negative MPNs, 5 (9.6 %) deaths were registered as a result of the blast transformation of the disease (n = 3) and thrombohemorrhagic complications (n = 2). CONCLUSION. Patients with Ph-negative MPNs and extrahepatic portal hypertension caused by portal vein thrombosis represent most complicated cases. However, surgical procedures, such as splenectomy combined with gastrotomy and esophageal/gastric variceal ligation, considerably improve long-term treatment outcomes despite a relatively high incidence of postoperative complications (thrombotic, hemorrhagic, purulent, and inflammatory ones).


  • Perioperative complications of splenectomy in hematological patients

    by E.S. Klimenko, K.I. Danishyan, O.A. Soboleva, N.I. Zozulya, E.A. Kitsenko

    Objective. To present the current stock of knowledge about perioperative complications of splenectomy for hematological disorders. Key issues. The use of minimally invasive technologies in hematological surgery has reduced the incidence of intra- and postoperative complications. However, both laparoscopic and open splenectomy are associated with technical difficulties in patients with blood diseases. Splenectomy is significantly complicated by severe splenomegaly, perisplenitis, portal hypertension, hemostatic disorders, severity of the hematological disease and the initial somatic condition of patients. Regardless of the selected approach, surgical (bleeding, pancreatic tail injury, pancreatic fistula, subdiaphragmatic abscess, etc.) and non-surgical (infections, portal system thrombosis) complications may develop in the perioperative period. Conclusion. Topographic and anatomical characteristics of the spleen, experience of the surgical team, as well as general condition of patients and the course of underlying disease and treatment modality play critical role in the development of perioperative complications.

  • Open Access

    Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)

    by M. V. Maevskaya, M. Yu. Nadinskaia, E. N. Bessonova, N. I. Geyvandova, M. S. Zharkova, E. A. Kitsenko, N. V. Korochanskaya, I. A. Kurkina, A. L. Melikyan, V. G. Morozov, et al.

    Introduction. As a result of portal hypertension (sequestration of platelets in an enlarged spleen) and liver failure (decreased production of thrombopoietin in the liver) in liver cirrhosis, thrombocytopenia develops, which is associated with the risk of periprocedural/perioperative bleeding complications. There are still unresolved questions regarding risk stratification of bleeding complications, the prognostic role of thrombocytopenia, as well as the need for treatment of thrombocytopenia and its methods.Materials and methods. The Russian Scientific Liver Society selected a panel of experts in the field of therapeutic and surgical hepatology, hematology, transfusion medicine to make reasoned statements and recommendations on the issue of treatment of thrombocytopenia before elective surgery / invasive procedures in patients with liver cirrhosis.Results. Relevant clinical issues were determined based on the PICO principle (patient or population, intervention, comparison, outcome). The Delphi panel made five questions and gave reasoned answers, framed as ‘clinical practice recommendations and statements’ with evidence-based comments. The questions and statements were based on the results of search and critical analysis of medical literature using keywords in English- and Russian-language databases. The formulated questions could be combined into four categories: bleeding risk stratification, the prognostic value of thrombocytopenia, the necessity and methods of thrombocytopenia drug correction, and bleeding risk reduction.Conclusions. The results of experts' work are directly related to high-quality management of patients with liver cirrhosis and thrombocytopenia, who have scheduled invasive procedures/surgery. Thus, this recommendations and statements can be used in clinical practice.


  • Extrahepatic portal hypertension in myeloproliferative diseases, features of diagnosis and therapeutic tactics

    by P.A. Batrov, E.A. Lukina, K.I. Danishyan, E.A. Kitsenko

    Myeloproliferative diseases are clonal diseases that occur at the level of a hematopoietic stem cell, characterized by the proliferation of one or more myelopoiesis cell lines in the bone marrow with signs of preserved terminal differentiation, accompanied by changes in peripheral blood parameters. The incidence rate of myeloproliferative diseases is in the range of 1—5 cases per 100 thousand adults and varies depending on the nosological form. Typical complications of myeloproliferative diseases are venous thrombosis of various localizations. Among the latter, a special place is occupied by thrombosis of the portal system vessels, leading to the development of extrahepatic portal hypertension and the formation of varicose veins of the esophagus and stomach, requiring surgical treatment. To date, for the prevention of bleeding from varicose veins of the esophagus and stomach, such surgical aids as endoscopic ligation of varicose veins of the esophagus and stomach, endovascular methods of treatment, such as the technology of transjugular intrahepatic portosystemic shunt (TIPS), various types of portocaval shunting, which have limitations in performing in patients with myeloproliferative diseases and total thrombosis, are used vessels of the portal system. In this regard, splenectomy in addition to gastrotomy, stitching of varicose veins of the esophagus and stomach (operation of M.D. Patsiora’s) is an effective treatment method that significantly reduces the risk of life-threatening bleeding from varicose veins of the esophagus and stomach and, accordingly, increase the duration and quality of life of patients with myeloproliferative diseases. In accordance with this, an important role is played not only by the choice of an operational intervention.


  • Open Access

    Liver transplantation in Budd–Chiari patients with history of portacaval shunt surgery

    by Д. А. Альтман, A. E. Poltorak, E. A. Kitsenko, B. Kh. Sarsenbaev, I. Ya. Bondarevsky, A. S. Ryzhikh, A. G. Istomin, T. E. Dorofeeva, M. A. Poltorak, E. M. Khalilov, et al.

    The paper presents the experience of successful treating a patient with diuretic-resistant ascites associated with Budd– Chiari syndrome. The authors provide a clinical observation of deceased donor liver transplantation to a patient with Budd–Chiari syndrome type 1, total hepatic vein occlusion, and diuretic-resistant ascites after portacaval shunt surgery. The post-transplantation period is observed as stable, with no signs of liver failure; ascites is reduced. The first experience of surgical treatment of a patient with Budd–Chiari syndrome, as well as the first experience of liver transplantation after portacaval shunting is appeared to be successful.

  • Rare sources of bleeding in extrahepatic portal hypertension developed after surgery on the organs of the gepatopancreatobiliary zone

    by A.E. Poltorak, E.A. Kitsenko, B.KH. Sarsenbaev, A.S. Ryzhikh, T.E. Dorofeeva, M.A. Poltorak, N.B. Nadtochii

    One of the causes of portal vein thrombosis and the formation of extrahepatic portal hypertension may be previous operations on the organs of the hepatoduodenal zone. Two cases of successful treatment of patients with extrahepatic portal hypertension, multiple bleeding into the lumen of the gastrointestinal tract (in the area of hepaticoejunoanastomosis, imposed earlier) are presented. In both cases, cavernous transformation of the portal vein was formed as a result of its thrombosis caused by the inflammatory process against the background of the course of the underlying disease and the postoperative period, as well as varicose veins of the hepatoduodenal ligament. Patients underwent surgery — laparotomy, mesentericocaval anastomosis «side to side». The immediate postoperative period is smooth. Under dynamic observation, bleeding into the lumen of the gastrointestinal tract did not recur. The observation period in one case is two years, in the second — one year.


  • Surgery in patients with severe or inhibitory hemophilia A under prevention injection of emicizumab

    by S.A. Shutov, N.I. Zozulya, V.A. Novikov, N.A. Shutova, A.I. Glebova, E.A. Kitsenko

    Возможность эффективно повышать коагуляционный потенциал крови, применяя современные гемостатические препараты, значительно снижает риск, связанный с хирургическим вмешательством, у больных гемофилией. Тем не менее послеоперационные осложнения геморрагического или тромботического характера возникают почти у 1/2 прооперированных пациентов. ЦЕЛЬ ИССЛЕДОВАНИЯ Определить особенности проведения гемостатической терапии и лабораторного контроля в периоперационном периоде у пациентов с тяжелой и ингибиторной формами гемофилии А при профилактическом лечении миметиком FVIII. МАТЕРИАЛ И МЕТОДЫ В период 2021—2022 гг. в ФГБУ «НМИЦ гематологии» были выполнены хирургические вмешательства 4 пациентам с тяжелой и ингибиторной формами гемофилии А. Все больные с целью профилактики специфических геморрагических проявлений гемофилии получали моноклональный антительный препарат эмицизумаб — первый препарат «нефакторной» терапии гемофилии. РЕЗУЛЬТАТЫ И ОБСУЖДЕНИЕ Определяющим моментом явилось выполнение хирургического вмешательства на фоне профилактического введения эмицизумаба. Дополнительную гемостатическую терапию либо не проводили, либо проводили в редуцированном режиме. Осложнений геморрагического либо тромботического характера, а также каких-либо побочных эффектов не было выявлено. Таким образом, применение так называемой нефакторной терапии является одним из вариантов решения проблемы «неуправляемости» гемостаза у пациентов с тяжелой и ингибиторной формами гемофилии. ЗАКЛЮЧЕНИЕ Профилактическое введение эмицизумаба создает некий буфер системы гемостаза, определенную и устойчивую нижнюю границу коагуляционного потенциала. Это является следствием стабильной концентрации эмицизумаба при использовании в любом из зарегистрированных режимов применения независимо от возраста и других индивидуальных особенностей пациента. Таким образом, исключается возможность возникновения острого массивного кровотечения. При этом не увеличивается риск тромбообразования, поскольку FVIII, имея бо́льшую по сравнению с эмицизумабом аффинность, вытесняет эмицизумаб из каскада свертывания, что не приводит к суммированию общего коагуляционного потенциала.